Intuitive Surgical, Inc. (ISRG) Q2 2025 Earnings Call Transcript

Intuitive Surgical (ISRG) reported strong Q2 2025 financial results, with revenue up 21% and pro forma EPS increasing 23% to $2.19, alongside 17% da Vinci procedure growth. The company initiated a broad U.S. launch of its da Vinci 5 system, leading to 180 placements of the new system and 83 trade-ins, while securing clearances for measured launches in Europe and Japan. While international procedure growth was robust in India and Korea, capital placements faced macro challenges in Europe, Japan, and China. New CEO Dave Rosa emphasized continued innovation, including the new vessel sealer curved and digital tools, as the company updated its 2025 da Vinci procedure growth guidance to 15.5%-17% and pro forma gross margin to 66%-67%, signaling confidence despite tariff impacts and ongoing manufacturing expansion.

Analysis

Intuitive Surgical reported a robust Q2 2025, marked by a 21% increase in revenue and a 23% rise in pro forma EPS to $2.19, reflecting strong underlying fundamentals. The primary growth driver was a 17% year-over-year increase in da Vinci procedures, with notable strength in U.S. benign general surgery and international non-urology procedures. The broad U.S. launch of the da Vinci 5 system has gained significant traction, evidenced by 180 placements of the new system and a substantial jump in trade-ins to 83, up from 21 in the prior year. While U.S. capital placements were strong, growing 45% YoY, international placements faced headwinds from macro challenges and budgetary constraints in Japan, China, and Europe. Despite these regional pressures, the company raised its full-year 2025 guidance for da Vinci procedure growth to a range of 15.5% to 17% and its pro forma gross margin forecast to 66% to 67%, signaling confidence in navigating tariff impacts and managing costs associated with its expanding manufacturing footprint. Growth in emerging platforms also continued, with Ion procedures up 52% and SP procedures up 88%, while the resumption of share repurchases ($181 million) underscores management's confidence in the company's valuation and outlook.

Key Decisions for Investors

• The strong results and raised guidance affirm the company's powerful commercial execution and the market's reception of the da Vinci 5, supporting a continued bullish stance on the core business.
• Investors should closely monitor the pace of the da Vinci 5 upgrade cycle, as the increase in trade-ins and higher ASPs will be a key driver of system revenue, while also tracking the international capital placement recovery following recent clearances in Europe and Japan.
• It is prudent to watch for any impact from the noted macro headwinds on international hospital capital budgets, as this remains the primary offsetting risk to the strong U.S. momentum.
• Consider the company's positioning against third-party instrument remanufacturing; the ongoing innovation with new instruments like the vessel sealer and the value proposition of the integrated da Vinci 5 ecosystem serve as key long-term competitive advantages.